Zai Lab Limited (HKG:9688)
29.65
+1.10 (3.85%)
Jun 6, 2025, 4:08 PM HKT
Zai Lab Revenue
Zai Lab had revenue of $106.49M USD in the quarter ending March 31, 2025, with 22.19% growth. This brings the company's revenue in the last twelve months to $418.33M, up 43.72% year-over-year. In the year 2024, Zai Lab had annual revenue of $398.99M with 49.59% growth.
Revenue (ttm)
$418.33M
Revenue Growth
+43.72%
P/S Ratio
9.56
Revenue / Employee
$223.82K
Employees
1,869
Market Cap
31.10B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines | 32.53B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
Innovent Biologics | 10.03B |
WuXi Biologics | 19.87B |
CSPC Pharmaceutical Group | 28.99B |
Sino Biopharmaceutical | 30.72B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
Zai Lab News
- 4 days ago - NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Benzinga
- 4 days ago - Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Business Wire
- 5 days ago - Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Business Wire
- 7 days ago - Zai Lab Announces Participation in Investor Conferences in June 2025 - Business Wire
- 9 days ago - Zai Lab Limited Is Well Positioned For Long-Term Growth - Seeking Alpha
- 15 days ago - Zai Lab Limited: Banking On Chinese Pharma Growth - Seeking Alpha
- 18 days ago - Zai Lab gets FDA fast track status for lung cancer treatment - Seeking Alpha
- 18 days ago - Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer - Business Wire